Rifampin(rif ’ am pin)
Rifadin, Rofact (CAN)
PREGNANCY CATEGORY C
Drug Classes
Antibiotic
Antituberculotic (first-line)
Therapeutic Actions
Inhibits DNA-dependent RNA polymerase activity in susceptible bacterial cells.
Indications
Treatment of pulmonary TB in conjunction with at least one other effective antituberculotic
Neisseria meningitidis carriers, for asymptomatic carriers to eliminate meningococci from nasopharynx; not for treatment of meningitis
Unlabeled uses: Infections caused by Staphylococcus aureus and Staphylococcus epidermidis, usually in combination therapy; gram-negative bacteremia in infancy; Legionella pneumophila infections not responsive to erythromycin; leprosy (in combination with dapsone); prophylaxis of meningitis caused by Haemophilus influenzae, catheter-related bloodstream infections (adults); cholestatic pruritus (adults)
Contraindications and Cautions
Contraindicated with allergy to any rifamycin, acute hepatic disease, lactation.
Use cautiously with pregnancy (teratogenic effects have been reported in preclinical studies; safest antituberculous regimen for use in pregnancy is considered to be rifampin, isoniazid, and ethambutol).
Available Forms
Capsules—150, 300 mg; powder for injection—600 mg
Dosages
Adults
Pulmonary TB: 10 mg/kg/day; not to exceed 600 mg in a single daily dose PO or IV (used in conjunction with other antituberculotics). Continue therapy until bacterial conversion and maximal improvement occur.
Meningococcal carriers: 600 mg PO or IV once daily for 4 consecutive days or 600 mg every 12 hr for 2 days.
Pediatric patients
Pulmonary TB:
1 mo and older: 10–20 mg/kg/day PO or IV not to exceed 600 mg/day.
Meningococcal carriers:
Younger than 1 mo: 5 mg/kg PO or IV every 12 hr for 2 days.
Older than 1 mo: 10 mg/kg PO or IV every 12 hr for 2 days, do not exceed 600 mg/dose.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
